SCHEMBL4720020

SCHEMBL4720020

COC(=O)CC1CN(C(=O)CCCCCCNc2ccccn2)CCc2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 11/20 0.46
ITGAV P06756 11/20 0.46
ITGA2B P08514 6/20 0.46
ITGB5 P18084 4/20 0.46
ITGB1 P05556 2/20 0.45
HDAC1 Q13547 4/20 0.39
HDAC6 Q9UBN7 3/20 0.39
DRD2 P14416 1/20 0.37
ADRA1A P35348 1/20 0.37
DRD3 P35462 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HSD17B10 Q99714 2/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
NOS2 P35228 1/20 0.37
DPP4 P27487 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4716833 0.90 ITGB3 (0.56) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4718352 0.82 ITGB3 (0.45) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4716846 0.81 ITGB3 (0.51) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4718116 0.80 ITGB3 (0.53) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4790307 0.77 ITGB3 (0.44) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4760965 0.77 NAMPT (0.45) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4789373 0.76 DPP4 (0.48) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL8487183 0.76 ITGB3 (0.42) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL14195948 0.76 ITGB3 (0.42) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL14195947 0.76 ITGB3 (0.42) ITGB3ITGAVITGA2BITGB5ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216230-B1 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC (US) 2008-04-23 EP disclosed
US-6514964-B1 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors AMGEN INC. 2003-02-04 US disclosed